Brief: Horizon Therapeutics Q2 Adjusted EPS USD 1.2 Vs. IBES Estimate USD 1.03
08/08/2023 12:00
Aug 08 (Reuters) - Horizon Therapeutics Q2 adjusted EBITDA USD 320.4 million. * Q2 adjusted net income USD 280.1 million * Q2 EPS USD 0.54 * Q2 sales USD 945 million vs. IBES estimate USD 867.7 million
Recent news on Horizon Therapeutics
See all newsDeals of the day-Mergers and acquisitions
Amgen completes $27.8 bln Horizon deal (updated)
Amgen completes acquisition of Horizon Therapeutics
Brief: Amgen Completes Acquisition Of Horizon Therapeutics PLC
On October 5, Court Sanctioned The Scheme Of Arrangement Under Chapter 1 Of Part 9 Of The Irish Companies Act 2014